English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background   Recently, a new tablet formulation of the widely used HIV protease inhibitor lopinavir/ritonavir was licensed. Here, we present a pilot study of the pharmaco-kinetics of the new adult tablet formulation taken once daily in children.Methods   Lopinavir pharmacokinetics of the new adult tablet formulation were evaluated in 15 HIV type-1-infected children between 4 and 15 years of age. A target dose of 460/115 mg/m 2  was administered once daily. Plasma concentrations of lopinavir over the course of 24 h were determined with a validated HPLC method.Results   The median lopinavir dose was 498 mg/m 2  (range 424–548). The mean ±sd for lopinavir area under the 24 h curve was 217.9 ±44.9 mg/l•h, the maximum concentration was 14.8 ±2.4 mg/l and the concentration 24 h after intake was 3.1 ±2.6 mg/l. The half-life of lopinavir was 5.8 ±4.5 h and the median time to maximum concentration was 5.8 h (range 1.8-12.2). Overall, the tablet formulation resulted in greater exposure to lopinavir with less variability compared with the soft-gel capsule formulation. All children treated with the new adult tablet formulation had undetectable viral loads (&lt;50 copies/ml) during 24 weeks follow-up.Conclusions   The tablet formulation could probably result in improved lopinavir dosing and increases the feasibility of once-daily lopinavir/ritonavir-based regimens in children.

Pharmacokinetics of Lopinavir in HIV Type-1-Infected Children Taking the New Tablet Formulation Once Daily